Cocrystal Initiates Phase 1b Norovirus Antiviral Challenge Study

Cocrystal Pharma ( (COCP) ) has provided an update.

On March 9, 2026, Cocrystal Pharma reported that the first subjects were dosed in a Phase 1b norovirus human challenge study at Emory University School of Medicine, evaluating its oral antiviral CDI-988 as both a preventive and treatment for norovirus infections. The randomized, double-blind, placebo-controlled trial will enroll up to 40 healthy adults, initially assessing the infectivity of the GII.2 Snow Mountain Virus inoculum before testing CDI-988 against placebo on endpoints including reduction of clinical symptoms, viral shedding, disease severity, and safety.

CDI-988, which targets a highly conserved region of the viral 3CL protease across known norovirus strains, previously showed favorable safety and tolerability in a Phase 1 trial and is described as the first oral direct-acting antiviral specifically developed for norovirus acute gastroenteritis. With no approved treatments or vaccines for norovirus and an estimated global economic burden of about $60 billion annually, the launch of this study marks a key operational milestone for Cocrystal and could strengthen its position in antiviral drug development if the data support further clinical advancement.

The most recent analyst rating on (COCP) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Neutral.

The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, shrinking equity base). Technicals also remain bearish with the stock below major moving averages, while positive corporate milestones (trial initiation steps, NIH funding, and insider financing) provide partial offset but do not fully mitigate the fundamental funding and execution risks.

To see Spark’s full report on COCP stock, click here.

More about Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses including SARS-CoV-2, noroviruses and hepatitis C viruses. The company uses proprietary structure-based drug discovery technologies and a structural biology platform to design broad-spectrum antiviral drugs for acute, chronic and potentially pandemic viral diseases.

The company’s approach combines expertise in enzymology and medicinal chemistry with three-dimensional structures of inhibitor complexes at near-atomic resolution. This enables rapid identification of novel binding sites and optimization of structure–activity relationships to advance oral antiviral candidates across multiple high-burden infectious disease markets.

Average Trading Volume: 71,734

Technical Sentiment Signal: Strong Sell

Current Market Cap: $13.92M

For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.